To evaluate safety and immunogenicity of two HIV-1 prophylactic vaccine regimens comprising Ad26.Mos4.HIV and either clade C gp140 or bivalent gp140
Latest Information Update: 01 Oct 2019
At a glance
- Drugs Ad26 Mos HIV (Primary) ; Ad26 Mos4 HIV (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacodynamics
- Acronyms ASCENT
Most Recent Events
- 01 Oct 2019 New trial record